Table 1 Sample characteristic according to the presence of clinical lipodystrophy
Without CL | With CL | P | |
|---|---|---|---|
n (%) | 139 (39.6) | 206 (58.7) | |
Sex [n(%)] | |||
Male | 85 (61.2) | 154 (74.8) | 0.007 |
Female | 54 (38.8) | 52 (25.2) | |
Age [years, median (25th and 75th percentiles)] | 42.0 (34.0-51.0) | 45.0 (39.0-54.0) | 0.006 |
Duration of HIV infection [years, median (25th and 75th percentiles)] | 6.0 (4.0-9.0) | 9.0 (6.0-11.0) | < 0.001 |
cART [years, median (25th and 75th percentiles)] | 4.0 (2.0-7.0) | 8.0 (5.0-10.0) | < 0.001 |
Weight [Kg, mean (sd)] | 73.6 (14.1) | 66.2 (12.4) | < 0.001 |
Height [m, mean (sd)] | 1.65 (0.09) | 1.66 (0.09) | 0.430 |
BMI [(kg/m2), mean (sd)] | 27.0 (5.0) | 24.0 (3.9) | < 0.001 |
Waist circumference [cm, mean (sd)] | 95.4 (13.0) | 89.5 (10.5) | < 0.001 |
Systolic BP [mmHg, median (25th and 75th percentiles)] | 120.0 (110.0-135.0) | 120.0 (110.0-135.0) | 0.871 |
Diastolic BP [mmHg, median (25th and 75th percentiles)] | 80.0 (70.0-80.0) | 80.0 (70.0-80.0) | 0.765 |
CD4 cell count [cells/mm3, median (25th and 75th percentiles)] | 446.5 (291.5-633.8) | 544.0 (362.0-749.0) | 0.008 |
HIV RNA (< 50) [n (%)] | 94 (82.5) | 163 (91.1) | 0.029 |
Hepatitis C co-infection [n (%)] | 31 (25) | 58 (31.4) | 0.227 |
HIV risk factor [n (%)] | |||
Intravenous drug user | 28 (24.6) | 52 (30.6) | |
Homosexual contact | 10 (8.8) | 19 (11.2) | |
Heterosexual contact | 75 (65.8) | 90 (52.9) | |
Others | 1 (0.9) | 9 (5.3) | 0.073 |
CDC [n (%)] | |||
A | 62 (54.9) | 94 (53.4) | |
B | 4 (3.5) | 0 (0.0) | |
C | 47 (41.6) | 82 (46.6) | 0.037 |
ART [n (%)] | |||
IP | 67 (61.5) | 98 (55.4) | 0.310 |
NNRTI | 47 (43.1) | 83 (46.9) | 0.534 |
NRTI | 104 (95.4) | 175 (98.9) | 0.066 |
Smoking history [n (%)] | |||
Never | 60 (43.5) | 70 (34.8) | |
Current | 56 (40.6) | 93 (46.3) | |
Former | 22 (15.9) | 38 (18.9) | 0.272 |
Glucose [mg/dL, median (25th and 75th percentiles)] | 91.0 (84.0-108.0) | 94.5 (863.0-117.0) | 0.074 |
Total cholesterol [mg/dL, mean (sd)] | 229.5 (59.8) | 220.7 (59.5) | 0.182 |
HDL- cholesterol [mg/dL, median (25th and 75th percentiles)] | 48.0 (37.0-55.0) | 43.0 (35.0-53.0) | 0.047 |
Triglycerides [mg/dL, median (25th and 75th percentiles)] | 192.0 (126.0-323.0) | 231.0 (149.8-365.8) | 0.016 |
Metabolic syndrome ATP III [n (%)] | 71 (51.1) | 109 (52.9) | 0.738 |
Metabolic syndrome IDF [n (%)] | 64 (46.0) | 85 (41.3) | 0.379 |
Metabolic syndrome features - ATP III | |||
High blood pressure | 61 (43.9) | 87 (42.4) | 0.790 |
Hypertriglyceridemia | 98 (70.5) | 177 (85.9) | < 0.001 |
Low HDL cholesterol | 93 (66.9) | 160 (77.7) | 0.027 |
High waist circumference | 58 (41.7) | 46 (22.3) | < 0.001 |
High fasting glucose | 51 (36.7) | 84 (40.8) | 0.446 |
Number of metabolic syndrome features ATP III | |||
0 | 6 (4.3) | 9 (4.4) | 0.242 |
1 | 25 (18.0) | 19 (9.3) | |
2 | 37 (26.6) | 69 (33.7) | |
3 | 31 (22.3) | 52 (25.4) | |
4 | 31 (22.3) | 42 (20.5) | |
5 | 9 (6.5) | 14 (6.8) | |
Metabolic syndrome features - IDF | |||
High blood pressure | 61 (43.9) | 87 (42.4) | 0.790 |
Hypertriglyceridemia | 98 (70.5) | 177 (85.9) | < 0.001 |
Low HDL cholesterol | 93 (66.9) | 160 (77.7) | 0.027 |
High waist circumference | 87 (62.6) | 94 (45.6) | 0.002 |
High fasting glucose | 51 (36.7) | 80 (38.8) | 0.687 |
Number of metabolic syndrome features IDF | |||
0 | 5 (3.6) | 9 (4.4) | 0.263 |
1 | 19 (13.7) | 17 (8.3) | |
2 | 35 (25.2) | 51 (24.9) | |
3 | 32 (23.0) | 63 (30.7) | |
4 | 35 (25.2) | 39 (19.0) | |
5 | 13 (9.4) | 26 (12.7) |